Category Archives: Cell Therapy

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/bvsbx5/cell_therapy) has announced the addition of the "Cell Therapy Partnering Yearbook 2013" report to their offering. The Cell Therapy Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report provide an orientation of 2012's dealmaking and business activities. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012. … Continue reading →

What Is Stem Cell Therapy? - Innovations Stem Cell Center http://www.InnovationsStemCellCenter.com 214.699.6948. By: InnovationsStemCell … Continue reading →

67 WALL STREET, New York - May 1, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation Companies include: Celgene Corporation (CELG), Amgen Inc. (AMGN), Celldex Therapeutics, Inc. (CLDX), Aastrom Biosciences, Inc. (ASTM), Pluristem Therapeutics, Inc. (PSTI), Arena Pharmaceuticals, Inc. (ARNA), Immunogen Inc. (IMGN) and many more. In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors: TWST: What have been some of the biggest successes and which have been the companies with the biggest successes? Mr. Peaker: In terms of successes in the oncology space, on the larger-cap side we've had some positive news from Celgene (CELG) for this drug called Pomalyst in myeloma. It's a relatively limited … Continue reading →

67 WALL STREET, New York - May 1, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation Companies include: Celgene Corporation (CELG), Amgen Inc. (AMGN), Celldex Therapeutics, Inc. (CLDX), Aastrom Biosciences, Inc. (ASTM), Pluristem Therapeutics, Inc. (PSTI), Arena Pharmaceuticals, Inc. (ARNA), Immunogen Inc. (IMGN) and many more. In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors: TWST: What have been some of the biggest successes and which have been the companies with the biggest successes? Mr. Peaker: In terms of successes in the oncology space, on the larger-cap side we've had some positive news from Celgene (CELG) for this drug called Pomalyst in myeloma. It's a relatively limited … Continue reading →

67 WALL STREET, New York - May 1, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation Companies include: Celgene Corporation (CELG), Amgen Inc. (AMGN), Celldex Therapeutics, Inc. (CLDX), Aastrom Biosciences, Inc. (ASTM), Pluristem Therapeutics, Inc. (PSTI), Arena Pharmaceuticals, Inc. (ARNA), Immunogen Inc. (IMGN) and many more. In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector for investors: TWST: What have been some of the biggest successes and which have been the companies with the biggest successes? Mr. Peaker: In terms of successes in the oncology space, on the larger-cap side we've had some positive news from Celgene (CELG) for this drug called Pomalyst in myeloma. It's a relatively limited … Continue reading →

ALLENDALE, N.J., April 29, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), announced today the execution of a Services Agreement with Sentien Biotechnologies, Inc. ("Sentien") under which PCT will provide services to support Sentien's development of its cell therapy product, including technology transfer, staff training, and manufacturing. Sentien is developing an allogeneic cell therapy product consisting of bone marrow derived mesenchymal stem cells seeded onto a medical device for critical care indications. Sentien has engaged PCT for manufacture of the final formulation of its cell therapy product and intends to transfer and implement Sentien's master cell bank, product working cell bank and product manufacturing processes to PCT. These cell banks will be prepared according to Good Manufacturing Practices ("GMP") guidelines and implemented by PCT to create a cell therapy product for Sentien's Investigational New Drug ("IND") submission to the FDA. Upon obtaining an IND, Sentien intends to have PCT manufacture GMP compliant grade materials to support Sentien's Phase I clinical trial. "We are excited to enter into this agreement with Sentien, an innovator for acute organ failure," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. PCT is an … Continue reading →

ALLENDALE, N.J., April 29, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), announced today the execution of a Services Agreement with Sentien Biotechnologies, Inc. ("Sentien") under which PCT will provide services to support Sentien's development of its cell therapy product, including technology transfer, staff training, and manufacturing. Sentien is developing an allogeneic cell therapy product consisting of bone marrow derived mesenchymal stem cells seeded onto a medical device for critical care indications. Sentien has engaged PCT for manufacture of the final formulation of its cell therapy product and intends to transfer and implement Sentien's master cell bank, product working cell bank and product manufacturing processes to PCT. These cell banks will be prepared according to Good Manufacturing Practices ("GMP") guidelines and implemented by PCT to create a cell therapy product for Sentien's Investigational New Drug ("IND") submission to the FDA. Upon obtaining an IND, Sentien intends to have PCT manufacture GMP compliant grade materials to support Sentien's Phase I clinical trial. "We are excited to enter into this agreement with Sentien, an innovator for acute organ failure," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. PCT is an … Continue reading →

Scottsdale Regenerative Cell Therapy treatment center, Premier Pain Institute, has opened up a new clinic that facilitates state of the art procedures for pain treatment. Scottsdale, Arizona (PRWEB) April 22, 2013 The philosophy of the new Scottsdale regenerative cell therapy center, the Premier Pain Institute is to treat each and every patient based on his or her specific diagnosis. With a one-on-one, doctor-to-patient, approach, the Premier Pain Institute ensures that every patient is carefully evaluated and diagnosed. Each patient then receives a specific treatment formulated to target the direct condition that is causing the pain. The Premier Pain Institute simply does not believe in a one-solution-cures-all methodology. Also, the Scottsdale regenerative cell therapy center, the Premier Pain Institute is not just for people with chronic back pain, but people suffering from carpal tunnel, post-surgical pain, hands/wrists/feet pain, headaches and neck pains, and more. Some of the treatment procedures include injections and transformational selective root sleeve injections. With many doctors, these injections usually involve the insertion of a singular large bore needle into the spine. Dr. Vengurlekar prefers to perform a more precise injection which uses a minimal amount of steroid and thus reduces the number of side effect risks that … Continue reading →

Public release date: 16-Apr-2013 [ | E-mail | Share ] Contact: Andreas M. Zeiher zeiher@em.uni-frankfurt.de The JAMA Network Journals Treatment that consisted of shock wave (procedure using high-dose ultrasound)-mediated preconditioning of the target heart tissue prior to administration of bone marrow-derived mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction) after 4 months in patients with chronic postinfarction heart failure, according to a study in the April 17 issue of JAMA. The results, which require confirmation in larger trials, demonstrate the potential for this type of therapy to reduce adverse clinical events in these chronically ill patients. "Regenerative therapies have emerged as a promising novel approach to improve heart function and prevent the development of end-stage heart failure. Application of various cell types including bone marrow-, heart tissue- or adipose tissue-derived cell populations were shown to improve cardiac functional recovery. In patients with acute myocardial infarction [heart attack], recent meta-analyses suggested a moderate but sustained enhancement of left ventricular function and improved clinical outcome following administration of bone marrow-derived mononuclear cells (BMCs)," according to background information in the article. "Extracorporeal … Continue reading →

Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1) Patient had a fall on 31st December 2012 due to whi... By: neurogenbsi … Continue reading →